26/08/2026
The problem isn’t the medication. It’s when marketing replaces medicine.
This fictional graphic is deliberately ridiculous. The questions behind it are not.
Obesity medications can be valuable, evidence-based treatments. Online care can also be excellent. This post critiques the models of care used by some providers—not people seeking treatment. The concern is when convenient access to a product is presented as comprehensive clinical care.
Red flags may include aggressive marketing, a focus on speed or guaranteed results, pressure to start immediately, referral codes or paid testimonials, vague information about risks and adverse effects, and no clear explanation of alternatives. Other concerns include no direct clinical conversation, limited access to an identifiable and appropriately qualified prescriber, and little or no follow-up after a prescription is issued.
A prescription should sit within an individualised treatment plan: comprehensive assessment, shared decision-making, clear guidance about options, dosing and adverse effects, a plan for what to do if concerns arise, and ongoing review.
Patients should understand why treatment is considered appropriate, how to use it safely, what to expect at different stages, which symptoms should prompt medical advice, how adverse effects will be managed, when treatment will be reviewed and who to contact if problems arise. A prescription without clear information, continuity or follow-up is not the same as comprehensive care.
Response should be considered in terms of health, function, quality of life and the person’s experience—not the scale alone.
Customer-service teams and automated systems may support care, but they cannot carry clinical responsibility.
Decisions requiring informed consent and clinical judgement should be guided by evidence, individual circumstances and patient preferences—not commercial pressure.
Obesity is a complex chronic disease. Access to medication matters. What surrounds the prescription matters too.